Food Safety Incidents

Adverse effects tachycardia and shortness of breath has been detected in Dietary supplement glamorous ozem.

Written by SGS Digicomply Editorial Team | Feb 27, 2026 11:00:00 PM

Incident Report: Dietary Supplement Adverse Effects

On February 12, 2026, an alarming incident was reported concerning a dietary supplement identified as glamorous ozem. The Brazilian Health Regulatory Agency, known as ANVISA, has raised concerns regarding adverse health effects associated with this product.

Individuals consuming the dietary supplement have experienced significant health issues, including tachycardia (an abnormally rapid heart rate) and shortness of breath. These symptoms are serious and warrant immediate attention, as they can indicate underlying health risks that may require medical intervention.

The origin of this issue has been traced back to Brazil, where the supplement was distributed. It is crucial for consumers to be aware of the potential risks associated with dietary supplements, particularly those that may not have undergone rigorous safety evaluations.

Health authorities recommend that individuals who have purchased this dietary supplement refrain from using it and consult healthcare professionals if they experience any adverse symptoms. Additionally, it is advised to report any side effects to health authorities to aid in monitoring and managing food safety concerns.

As the situation develops, further investigations will be conducted to determine the extent of the issue and to ensure consumer safety. It is imperative for consumers to stay informed and prioritize their health by being cautious with dietary supplements.

  • Incident: Adverse effects tachycardia and shortness of breath has been detected in Dietary supplement glamorous ozem.
  • Date: 2026-02-12
  • Product: Dietary supplement glamorous ozem
  • Market: Available to SGS Digicomply users only. Explore the platform (for enterprises, no individual plans)
  • Origin of issue: Brazil
  • Hazard: Available to SGS Digicomply users only. Explore the platform (for enterprises, no individual plans)
  • Incident Category: Control
  • Source: Brazilian Health Regulatory Agency - ANVISA